Purple Biotech Ltd
PPBT
$3.95
$0.102.55%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -4.84% | -- | -68.37% | -- | |
| Gross Profit | 4.84% | -- | 68.37% | -- | |
| SG&A Expenses | 116.94% | -21.04% | -40.17% | -32.21% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 191.63% | -62.04% | -83.79% | -62.88% | |
| Operating Income | -191.63% | 62.04% | 83.79% | 62.88% | |
| Income Before Tax | -5,596.87% | 54.91% | 91.46% | 86.79% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -5,596.87% | 54.91% | 91.46% | 86.79% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | 1,840.00% | -60.00% | -83.87% | -73.68% | |
| Net Income | -5,642.68% | 54.89% | 91.51% | 86.83% | |
| EBIT | -191.63% | 62.04% | 83.79% | 62.88% | |
| EBITDA | -188.83% | 62.92% | 83.89% | 63.42% | |
| EPS Basic | -890.00% | 77.01% | 94.65% | 91.77% | |
| Normalized Basic EPS | -33.33% | 76.00% | 94.87% | -- | |
| EPS Diluted | -890.00% | 77.01% | 94.71% | 91.77% | |
| Normalized Diluted EPS | -33.33% | 76.00% | 94.87% | -- | |
| Average Basic Shares Outstanding | 480.53% | 98.77% | 59.08% | 58.69% | |
| Average Diluted Shares Outstanding | 480.53% | 98.77% | 59.08% | 58.69% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |